Yiporo Danyuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yiporo Danyuo has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Winnston Oluwole Soboyejo
Global Center of Advanced Materials and Manufacturing (GCAMM), College of Engineering, SUNY Polytechnic Institute Utica New York USA
13 shared publications - Olushola S. Odusanya
Department of Materials Science and Engineering, African University of Science and Technology (AUST) Abuja, Federal Capital Territory, Nigeria; Sheda Science and Technology Complex (SHESTCO) Abuja, Federal Capital Territory, Nigeria
11 shared publications - Stella Dozie‐Nwachukwu
Department of Materials Science and Engineering, African University of Science and Technology (AUST), Abuja, Federal Capital Territory, Nigeria
10 shared publications K. Malatesta
Princeton Institute for the Science and Technology of Materials (PRISM), and The Department of Mechanical and Aerospace Engineering, Princeton University, Princeton, NJ 08544, USA
9 shared publicationsJ.D. Obayemi
Department of Mechanical Engineering, Worcester Polytechnic Institute (WPI), Worcester, MA 01609, USA
6 shared publicationsN. Anuku
Princeton Institute of Science and Technology of Materials (PRISM), Bowen Hall, 70 Prospect Street, Princeton, NJ, 08544, USA
6 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1498
Engineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure–Property–Performance Design Perspective
Background/Objectives: Cancer therapy remains limited by poor tumor selectivity, systemic toxicity, biological barriers to drug transport, rapid clearance, treatment resistance, and postoperative recurrence. Functional biomaterials offer engineered systems to address these limitations through targeted, localized, controlled, and stimuli-responsive drug delivery. However, existing reviews commonly classify these systems according to carrier type, therapeutic agent, or cancer application, with less emphasis on how biomaterial structure and physicochemical properties determine therapeutic performance. This review addresses this gap using a structure–property–performance (SPP) framework to rationally engineer functional biomaterials for targeted, localized cancer drug delivery. Methods: The review critically examines particle size and morphology, surface chemistry and charge, targeting functionalization, stimulus responsiveness, porosity and internal architecture, mechanical stability, and degradation, and relates these design parameters to drug loading and release, systemic transport, tumor accumulation and penetration, cellular uptake, and local retention. Selected mechanistic relationships, including equations for particle diffusion, membrane wrapping, receptor-mediated endocytosis, particle aspect ratio, porous-matrix transport, implant-associated tissue diffusion, and porosity-dependent stiffness, are also discussed to support quantitative interpretation of SPP relationships. The review further evaluates these relationships across cancer-specific biomaterial applications. Results: The reviewed evidence shows that biomaterial properties are strongly interdependent and often involve competing requirements, so optimizing one property can improve one aspect of therapeutic performance while limiting another. Cancer-specific applications in breast, brain, colorectal, pancreatic, melanoma, ovarian, bladder, and bone cancers further demonstrate that effective biomaterial design must be matched to disease-specific biological and anatomical barriers. Conclusions: The SPP framework provides a design approach for moving functional biomaterials from empirical formulation toward integrated, application-specific design. Future development is expected to increasingly incorporate AI-guided and personalized design, image-guided delivery, multi-responsive functionality, and integration of cancer therapy with tissue regeneration to advance more precise and clinically translatable cancer treatments.
- 21 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1498
Open AccessEngineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure–Property–Performance Design Perspective
Background/Objectives: Cancer therapy remains limited by poor tumor selectivity, systemic toxicity, biological barriers to drug transport, rapid clearance, treatment resistance, and postoperative recurrence. Functional biomaterials offer engineered systems to address these limitations through targeted, localized, controlled, and stimuli-responsive drug delivery. However, existing reviews commonly classify these systems according to carrier type, therapeutic agent, or cancer application, with less emphasis on how biomaterial structure and physicochemical properties determine therapeutic performance. This review addresses this gap using a structure–property–performance (SPP) framework to rationally engineer functional biomaterials for targeted, localized cancer drug delivery. Methods: The review critically examines particle size and morphology, surface chemistry and charge, targeting functionalization, stimulus responsiveness, porosity and internal architecture, mechanical stability, and degradation, and relates these design parameters to drug loading and release, systemic transport, tumor accumulation and penetration, cellular uptake, and local retention. Selected mechanistic relationships, including equations for particle diffusion, membrane wrapping, receptor-mediated endocytosis, particle aspect ratio, porous-matrix transport, implant-associated tissue diffusion, and porosity-dependent stiffness, are also discussed to support quantitative interpretation of SPP relationships. The review further evaluates these relationships across cancer-specific biomaterial applications. Results: The reviewed evidence shows that biomaterial properties are strongly interdependent and often involve competing requirements, so optimizing one property can improve one aspect of therapeutic performance while limiting another. Cancer-specific applications in breast, brain, colorectal, pancreatic, melanoma, ovarian, bladder, and bone cancers further demonstrate that effective biomaterial design must be matched to disease-specific biological and anatomical barriers. Conclusions: The SPP framework provides a design approach for moving functional biomaterials from empirical formulation toward integrated, application-specific design. Future development is expected to increasingly incorporate AI-guided and personalized design, image-guided delivery, multi-responsive functionality, and integration of cancer therapy with tissue regeneration to advance more precise and clinically translatable cancer treatments.
- Open Access
- 31 August 2026
- Published by MDPI AG in Preprints.org
Engineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure-Property-Performance Design Perspective
Background/Objectives: Cancer therapy remains limited by poor tumor selectivity, systemic toxicity, biological barriers to drug transport, rapid clearance, treatment resistance, and postoperative recurrence. Functional biomaterials offer engineered systems to address these limitations through targeted, localized, controlled, and stimuli-responsive drug delivery. However, existing reviews commonly classify these systems according to carrier type, therapeutic agent, or cancer application, with less emphasis on how biomaterial structure and physicochemical properties determine therapeutic performance. This review addresses this gap using a structure-property-performance (SPP) framework for the rational engineering of functional biomaterials for targeted and localized cancer drug delivery. Methods: The review critically examines particle size and morphology, surface chemistry and charge, targeting functionalization, stimulus responsiveness, porosity and internal architecture, mechanical stability, and degradation, and relates these design parameters to drug loading and release, systemic transport, tumor accumulation and penetration, cellular uptake, and local retention. The review further evaluates these relationships across cancer-specific biomaterial applications. Results: The reviewed evidence shows that biomaterial properties are strongly interdependent and often involve competing requirements, so optimizing one property can improve one aspect of therapeutic performance while limiting another. Cancer-specific applications in breast, brain, colorectal, pancreatic, melanoma, ovarian, bladder, and bone cancers further demonstrate that effective biomaterial design must be matched to disease-specific biological and anatomical barriers. Conclusions: The SPP framework provides a design approach for moving functional biomaterials from empirical formulation toward integrated, application-specific design. Future development is expected to increasingly incorporate AI-guided and personalized design, image-guided delivery, multi-responsive functionality, and integration of cancer therapy with tissue regeneration to advance more precise and clinically translatable cancer treatments.
- 31 August 2026
- Published by MDPI AG in Preprints.org
Open AccessEngineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure-Property-Performance Design Perspective
Background/Objectives: Cancer therapy remains limited by poor tumor selectivity, systemic toxicity, biological barriers to drug transport, rapid clearance, treatment resistance, and postoperative recurrence. Functional biomaterials offer engineered systems to address these limitations through targeted, localized, controlled, and stimuli-responsive drug delivery. However, existing reviews commonly classify these systems according to carrier type, therapeutic agent, or cancer application, with less emphasis on how biomaterial structure and physicochemical properties determine therapeutic performance. This review addresses this gap using a structure-property-performance (SPP) framework for the rational engineering of functional biomaterials for targeted and localized cancer drug delivery. Methods: The review critically examines particle size and morphology, surface chemistry and charge, targeting functionalization, stimulus responsiveness, porosity and internal architecture, mechanical stability, and degradation, and relates these design parameters to drug loading and release, systemic transport, tumor accumulation and penetration, cellular uptake, and local retention. The review further evaluates these relationships across cancer-specific biomaterial applications. Results: The reviewed evidence shows that biomaterial properties are strongly interdependent and often involve competing requirements, so optimizing one property can improve one aspect of therapeutic performance while limiting another. Cancer-specific applications in breast, brain, colorectal, pancreatic, melanoma, ovarian, bladder, and bone cancers further demonstrate that effective biomaterial design must be matched to disease-specific biological and anatomical barriers. Conclusions: The SPP framework provides a design approach for moving functional biomaterials from empirical formulation toward integrated, application-specific design. Future development is expected to increasingly incorporate AI-guided and personalized design, image-guided delivery, multi-responsive functionality, and integration of cancer therapy with tissue regeneration to advance more precise and clinically translatable cancer treatments.
- Open Access
- 10 March 2026
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 17 (3) , 134
LHRH-Conjugated Magnetite Nanoparticles and Nanorods as Magnetic Resonance Imaging Contrast Agents for Targeting Triple-Negative Breast Cancer
This paper presents the results of an experimental study on the effects of magnetite nanoparticle (MNP) shape on magnetic resonance imaging (MRI) of triple-negative breast cancer (TNBC) xenograft tissues. T2-weighted MRI scans using spherical shaped MNPs as contrast agents are compared to MRI scans done with nanorod-shaped MNPs as contrast agents. The MNPs were first coated with polyethylene glycol (PEG) and subsequently conjugated to luteinizing hormone-releasing hormone (LHRH) to specifically target LHRH receptors, which are present at high levels on the surfaces of xenograft TNBC cells/tissues. After 3 weeks of tumor growth in nude immunocompromised mice, LHRH-conjugated (functionalized) and unconjugated (non-functionalized) MNPs were injected into the immunocompromised mice. Four types of MNPs were used: non-functionalized nanorod-shaped MNPs (BMNR); LHRH-conjugated nanorod-shaped MNPs (LCMNR); non-functionalized spherical-shaped MNPs (BSSMNP); and LHRH-conjugated spherical-shaped MNPs (LCSSMNP). T2-weighted magnetic resonance imaging (MRI) scans were obtained from the mice before the injection of the MNPs and two hours after the injection of the MNPs. The results show that using nanorod-shaped LHRH-conjugate MNPs as contrast agents yielded higher-resolution T2-weighted MRI scans of TNBC tumors compared to those from spherical-shaped MNPs. The implications of the results are discussed in relation to potential applications of functionalized MNPs in MRI for TNBC diagnosis.
- 10 March 2026
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 17 (3) , 134
Open AccessLHRH-Conjugated Magnetite Nanoparticles and Nanorods as Magnetic Resonance Imaging Contrast Agents for Targeting Triple-Negative Breast Cancer
This paper presents the results of an experimental study on the effects of magnetite nanoparticle (MNP) shape on magnetic resonance imaging (MRI) of triple-negative breast cancer (TNBC) xenograft tissues. T2-weighted MRI scans using spherical shaped MNPs as contrast agents are compared to MRI scans done with nanorod-shaped MNPs as contrast agents. The MNPs were first coated with polyethylene glycol (PEG) and subsequently conjugated to luteinizing hormone-releasing hormone (LHRH) to specifically target LHRH receptors, which are present at high levels on the surfaces of xenograft TNBC cells/tissues. After 3 weeks of tumor growth in nude immunocompromised mice, LHRH-conjugated (functionalized) and unconjugated (non-functionalized) MNPs were injected into the immunocompromised mice. Four types of MNPs were used: non-functionalized nanorod-shaped MNPs (BMNR); LHRH-conjugated nanorod-shaped MNPs (LCMNR); non-functionalized spherical-shaped MNPs (BSSMNP); and LHRH-conjugated spherical-shaped MNPs (LCSSMNP). T2-weighted magnetic resonance imaging (MRI) scans were obtained from the mice before the injection of the MNPs and two hours after the injection of the MNPs. The results show that using nanorod-shaped LHRH-conjugate MNPs as contrast agents yielded higher-resolution T2-weighted MRI scans of TNBC tumors compared to those from spherical-shaped MNPs. The implications of the results are discussed in relation to potential applications of functionalized MNPs in MRI for TNBC diagnosis.
- 23 October 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 109-115
Measuring the Efficacy of a Locally Manufactured Face Shield
The need for growth in Africa's manufacturing ecosystem was highlighted by the COVID-19 pandemic as personal protective equipment (PPE) had to largely be imported. This paper presents the design, fabrication and testing of a face shield produced using locally available materials and methods in Ghana. User research with medical professionals and other PPE users revealed issues with existing commercial face shields such as high cost, poor durability, and discomfort. An improved face shield design was developed, leveraging fabrication methods employed by local tailors. An elastic/foam band made from African fabric was integrated with a plastic sheet, the former being reusable and the latter being disposable. A series of flow visualization experiments were used to determine the efficacy of this shield against that of the commercial counterpart. Particle count and velocity flow field results revealed superior performance of the local design in terms of particle blocking. This study underscores the potential for decentralized manufacturing in Africa, providing a model for creating effective, affordable and accessible PPE using indigenous resources and simple production techniques.
- 23 October 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 109-115
Measuring the Efficacy of a Locally Manufactured Face Shield
The need for growth in Africa's manufacturing ecosystem was highlighted by the COVID-19 pandemic as personal protective equipment (PPE) had to largely be imported. This paper presents the design, fabrication and testing of a face shield produced using locally available materials and methods in Ghana. User research with medical professionals and other PPE users revealed issues with existing commercial face shields such as high cost, poor durability, and discomfort. An improved face shield design was developed, leveraging fabrication methods employed by local tailors. An elastic/foam band made from African fabric was integrated with a plastic sheet, the former being reusable and the latter being disposable. A series of flow visualization experiments were used to determine the efficacy of this shield against that of the commercial counterpart. Particle count and velocity flow field results revealed superior performance of the local design in terms of particle blocking. This study underscores the potential for decentralized manufacturing in Africa, providing a model for creating effective, affordable and accessible PPE using indigenous resources and simple production techniques.
- Open Access
- 28 July 2024
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 15 (8) , 209
Luteinizing Hormone-Releasing Hormone (LHRH)-Conjugated Cancer Drug Delivery from Magnetite Nanoparticle-Modified Microporous Poly-Di-Methyl-Siloxane (PDMS) Systems for the Targeted Treatment of Triple Negative Breast Cancer Cells
This study presents LHRH conjugated drug delivery via a magnetite nanoparticle-modified microporous Poly-Di-Methyl-Siloxane (PDMS) system for the targeted suppression of triple-negative breast cancer cells. First, the MNP-modified PDMS devices are fabricated before loading with targeted and untargeted cancer drugs. The release kinetics from the devices are then studied before fitting the results to the Korsmeyer–Peppas model. Cell viability and cytotoxicity assessments are then presented using results from the Alamar blue assay. Apoptosis induction is then elucidated using flow cytometry. The in vitro drug release studies demonstrated a sustained and controlled release of unconjugated drugs (Prodigiosin and paclitaxel) and conjugated drugs [LHRH conjugated paclitaxel (PTX+LHRH) and LHRH-conjugated prodigiosin (PG+LHRH)] from the magnetite nanoparticle modified microporous PDMS devices for 30 days at 37 °C, 41 °C, and 44 °C. At 24, 48, 72, and 96 h, the groups loaded with conjugated drugs (PG+LHRH and PTX+LHRH) had a significantly higher (p < 0.05) percentage cell growth inhibition than the groups loaded with unconjugated drugs (PG and PTX). Additionally, throughout the study, the MNP+PDMS (without drug) group exhibited a steady rise in the percentage of cell growth inhibition. The flow cytometry results revealed a high incidence of early and late-stage apoptosis. The implications of the results are discussed for the development of biomedical devices for the localized and targeted release of cancer drugs that can prevent cancer recurrence following tumor resection.
- 28 July 2024
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 15 (8) , 209
Open AccessLuteinizing Hormone-Releasing Hormone (LHRH)-Conjugated Cancer Drug Delivery from Magnetite Nanoparticle-Modified Microporous Poly-Di-Methyl-Siloxane (PDMS) Systems for the Targeted Treatment of Triple Negative Breast Cancer Cells
This study presents LHRH conjugated drug delivery via a magnetite nanoparticle-modified microporous Poly-Di-Methyl-Siloxane (PDMS) system for the targeted suppression of triple-negative breast cancer cells. First, the MNP-modified PDMS devices are fabricated before loading with targeted and untargeted cancer drugs. The release kinetics from the devices are then studied before fitting the results to the Korsmeyer–Peppas model. Cell viability and cytotoxicity assessments are then presented using results from the Alamar blue assay. Apoptosis induction is then elucidated using flow cytometry. The in vitro drug release studies demonstrated a sustained and controlled release of unconjugated drugs (Prodigiosin and paclitaxel) and conjugated drugs [LHRH conjugated paclitaxel (PTX+LHRH) and LHRH-conjugated prodigiosin (PG+LHRH)] from the magnetite nanoparticle modified microporous PDMS devices for 30 days at 37 °C, 41 °C, and 44 °C. At 24, 48, 72, and 96 h, the groups loaded with conjugated drugs (PG+LHRH and PTX+LHRH) had a significantly higher (p < 0.05) percentage cell growth inhibition than the groups loaded with unconjugated drugs (PG and PTX). Additionally, throughout the study, the MNP+PDMS (without drug) group exhibited a steady rise in the percentage of cell growth inhibition. The flow cytometry results revealed a high incidence of early and late-stage apoptosis. The implications of the results are discussed for the development of biomedical devices for the localized and targeted release of cancer drugs that can prevent cancer recurrence following tumor resection.
- 5 June 2023
- Published by Springer Nature in MRS Advances
- Vol. 8 (13) , 743-749
Design and optimization of water filtration systems for Ghanaian households
- 5 June 2023
- Published by Springer Nature in MRS Advances
- Vol. 8 (13) , 743-749
Design and optimization of water filtration systems for Ghanaian households
- 23 June 2022
- Published by Springer Nature in MRS Advances
- Vol. 7 (30) , 656-662
Surface coating and wettability study of PDMS-based composites: Effect on contact angle and cell-surface interaction
- 23 June 2022
- Published by Springer Nature in MRS Advances
- Vol. 7 (30) , 656-662
Surface coating and wettability study of PDMS-based composites: Effect on contact angle and cell-surface interaction
- 29 April 2021
- Published by Wiley in Journal of Food Safety
- Vol. 41 (4) , e12904
Release kinetics of fungicidal antimicrobials into packaged foods
This article presents the release kinetics (RK) of a fungicidal antimicrobial agent (AMA), potassium sorbate (PS), that prolongs the shelf life of packaged food. The effects of PS release are explored on peanut and fresh bread to determine the effects of PS on Aspergillus niger (AN) microbe growth. The AN was cultured in a potato dextrose agar (PDA) medium to obtain AMA activity on the film. AMA activity of PS incorporated into cellulose acetate (CA) based film was tested on peanuts and fresh bread for an extended period of time. The RK of PS from the films was obtained by studying the de‐swelling properties of PS loaded film at room temperature (24°C) and at elevated temperature (37°C). The diffusion coefficients of PS released through the film network were obtained to be between 8.32 × 10−10 to 7.3 × 10−7 m2/s. The release exponents (n) of PS from the film occurred by anomalous transport with n‐values ranging from 0.13 to 0.16 at 24°C and 0.5 to 0.89 at 37°C. The average flux released from the CA film was consistent with the percentage PS release from the CA film showing that modeling the effective diffusion of PS from a porous media is feasible. The released PS was potent enough to inhibit the growth of AN for a week then over a period of 2 years. Thereafter, the implications of the results in designing smart food packaging for enhanced food preservation were discussed.
- 29 April 2021
- Published by Wiley in Journal of Food Safety
- Vol. 41 (4) , e12904
Release kinetics of fungicidal antimicrobials into packaged foods
This article presents the release kinetics (RK) of a fungicidal antimicrobial agent (AMA), potassium sorbate (PS), that prolongs the shelf life of packaged food. The effects of PS release are explored on peanut and fresh bread to determine the effects of PS on Aspergillus niger (AN) microbe growth. The AN was cultured in a potato dextrose agar (PDA) medium to obtain AMA activity on the film. AMA activity of PS incorporated into cellulose acetate (CA) based film was tested on peanuts and fresh bread for an extended period of time. The RK of PS from the films was obtained by studying the de‐swelling properties of PS loaded film at room temperature (24°C) and at elevated temperature (37°C). The diffusion coefficients of PS released through the film network were obtained to be between 8.32 × 10−10 to 7.3 × 10−7 m2/s. The release exponents (n) of PS from the film occurred by anomalous transport with n‐values ranging from 0.13 to 0.16 at 24°C and 0.5 to 0.89 at 37°C. The average flux released from the CA film was consistent with the percentage PS release from the CA film showing that modeling the effective diffusion of PS from a porous media is feasible. The released PS was potent enough to inhibit the growth of AN for a week then over a period of 2 years. Thereafter, the implications of the results in designing smart food packaging for enhanced food preservation were discussed.
- 1 May 2020
- Published by Springer Nature in MRS Advances
- Vol. 5 (26) , 1377-1385
Laser Application of Nanocomposite Hydrogels on Cancer Cell Viability
- 1 May 2020
- Published by Springer Nature in MRS Advances
- Vol. 5 (26) , 1377-1385
Laser Application of Nanocomposite Hydrogels on Cancer Cell Viability
- 1 May 2020
- Published by Springer Nature in MRS Advances
- Vol. 5 (26) , 1367-1375
Development of a Low-cost Biomedical Device to Enhance Pneumonia Diagnosis in Children
- 1 May 2020
- Published by Springer Nature in MRS Advances
- Vol. 5 (26) , 1367-1375
Development of a Low-cost Biomedical Device to Enhance Pneumonia Diagnosis in Children